HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Sumatriptan Succinate

HCID 59772
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
103628-48-4
Standard SMILES
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1.O=C(O)CCC(=O)O
InChIKey
PORMUFZNYQJOEI-UHFFFAOYSA-N
Molecular formula
C18H27N3O6S
Average molar mass
413.5 g/mol
Monoisotopic mass
413.16205676

Overview

Sumatriptan succinate is a succinate salt obtained by reaction of sumatriptan with one equivalent of succinic acid. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used for the acute treatment of migraine with or without aura in adults. It has a role as a serotonergic agonist and a vasoconstrictor agent. It contains a sumatriptan(1+).

Names & identifiers

Preferred name
Sumatriptan Succinate
IUPAC
butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
English name
Sumatriptan succinate
Molecular formula
C18H27N3O6S
Molecular weight
413.48848

Names & synonyms

SUMATRIPTAN SUCCINATE103628-48-4Sumavel DoseProAlsumaOnzetra XsailImitrex StatdoseGR 43175CZembrace SymTouchSumatriptan GalpharmSumatriptan (as succinate)GR-43175CNSC-760362
Show more names
SuMitrexgr43175cSumatriptan succinatSuccinate Sumatriptanmethanesulfonamide(1:1)SumatriptanSuccinate>Penehyclidine Impurity 9SUMATRIPTANSUCCINATE(1:1)SuMatriptan Succinate, EP
J8BDZ68989CHEBI:64359DTXSID60145966ZecuityImigran subjectMigraleve ultraMigraine PackImigran 50

Database identifiers

CAS
103628-48-4
PubChem CID
59772
DTXSID
DTXSID60145966
ChEMBL
CHEMBL1201150
ChEBI

Properties

Computed structural properties

Topological polar surface area
148 Ų
Hydrogen bond donors
4
Hydrogen bond acceptors
8
Rotatable bonds
9
Heavy atoms
28
Formal charge
0
Complexity
498

Experimental & physicochemical properties

Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Triptans; Vasoconstrictor Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physicochemical properties

Melting point
165 · 165-166°C
storage temp.
-20 °C · -20°C
solubility
2 O: · H2O: >20mg/mL
form
solid
color
white to off-white
Merck
14 · 14,8997
BCS Class
3 · 3
Major Application
pharmaceutical (small molecule)
InChI
1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
InChIKey
PORMUFZNYQJOEI-UHFFFAOYSA-N
SMILES
OC(=O)CCC(O)=O.CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H318 (79.6%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

P203, P264+P265, P273, P280, P305+P354+P338, P317, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 54 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationSumatriptan succinate: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesEye Dam. 1 (79.6%)

Toxicology

Exposure RoutesSubcutaneous, Oral, Nasal, Transdermal
Toxicity Summary · 1 item

The 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors function as autoreceptors, which inhibit the firing of serotonin neurons and a reduction in the synthesis and release of serotonin upon activation. After sumatriptan binds to these receptors, adenylate cyclase activity is inhibited via regulatory G proteins, incrases intracellular calcium, and affects other intracellular events. This results in vasoconstriction and inhibtion of sensory nociceptive (trigeminal) nerve firing and vasoactive neuropeptide release. Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation. Sumatriptan also blocks the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during migraine and may inhibit the release of inflammatory mediators from the trigeminal nerve.

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 1 item

Hepatic. In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme. Route of Elimination: Only 3% of the dose is excreted in the urine as unchanged sumatriptan; 42% of the dose is excreted as the major metabolite, the indole acetic acid analogue of sumatriptan. Half Life: 2.5 hours

FDA Pharmacological Classification · 2 items

SUMATRIPTAN SUCCINATE

Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]; Serotonin 1d Receptor Agonists [MoA]; Serotonin 1b Receptor Agonists [MoA]

MeSH Pharmacological Classification · 2 items

Drugs used to cause constriction of the blood vessels.

Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.

Uses & manufacturing

UsesFor the treatment of migraine attacks with or without aura.
Applications · 7 items

DescriptionSumatriptan succinate is a synthetic drug belonging to a class of medications known as 5-hydroxytryptamine agonists (also called "triptans"), which is commonly used to treat cluster and migraine headaches with or without aura (warning signs occurring prior to the onset of a migraine). It is effective to relieve or eliminate the intensity of migraine and cluster headaches and accompanying symptoms including sensitivity to light or sound, nausea, and vomiting. However, it cannot help prevent future migraines/headaches or decrease the frequency of getting migraine and it is not recommended for other types of headache or for headache prevention. It is believed that the pain of migraine headaches is induced by dilated blood vessels inside the head. Sumatriptan succinate relieves migraine headaches by affecting the serotonin in the brain, which results in constriction of blood vessels. Subcutaneous injection of this drug is more effective than other formulations.

Related reactions

2 records
New reaction record
HRID 1625661 reaction equation
HRID 1625661As reactant
HRID 1797389 reaction equation
HRID 1797389As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CHEBI:64359
UNII
J8BDZ68989
EC Number
600-463-4
CAS DataBase Reference
103628 · 103628-48-4(CAS DataBase Reference)
FDA UNII
8 BDZ68989 · J8BDZ68989
NCI Drug Dictionary
sumatriptan succinate
Comptox DTXSID
60145966 · DTXSID60145966
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Symbol(GHS)
8 · GHS08
Signal word
Warning
Hazard statements
361 d-H412 · H361d-H412
Precautionary statements
202 · P202-P273-P280-P308+P313-P405-P501
Hazard Codes
Xi
Risk Statements
36 · 36/37/38-41
Safety Statements
26 · 26-36-39
RIDADR
3077 · 3077
WGK Germany
3 · 3
RTECS
9940000 · EJ9940000
HS Code
2935900090 · 2935900090
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
3 Repr · Aquatic Chronic 3Repr. 2
Signs and SymptomsSymptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sumatriptan succinate

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
3
rtecs
EJ9940000
ridadr
3077
hs_code
2935900090
risk_code
36/37/38-41
Signal word
Warning
Symbol(GHS)
GHS08
hazard_code
Xi
safety_code
26-36-39
Storage Class
11 - Combustible Solids
Hazard statements
H361d-H412
Hazard Classifications
Aquatic Chronic 3Repr. 2
Precautionary statements
P202-P273-P280-P308+P313-P405-P501

DescriptionSumatriptan succinate is a highly selective 5HT1-like receptor agonist introduced as a new treatment for migraine. It is indicated for the acute relief of migraine and cluster headache. Oral administration is reported to be free of substantial side effects. The compound appears to be a significant advance over the use of ergotamine and other agents in the treatment of migraine.

UsesA serotonin 5HT1-receptor agonist

UsesH1-antihistamine

UsesA selective 5-HT1 receptor agonist

UsesSumatriptan (succinate) is a serotonin 5-hydroxytryptamine 1 (5-HT1) receptor agonist with selective affinity for 5-HT1B and 5-HT1D receptors with IC50 values of 9.3 and 7.3 nM, respectively. It also has affinity for the 5-HT1F receptor (IC50 = 17.8 nM). Sumatriptan (succinate) has been shown to induce vasoconstriction of human middle meningeal arteries (EC50 = 89.9 nM) and reduce vascular inflammation associated with migraines.

UsesSumatriptan Succinate is a selective 5-HT1B/1D-receptor agonist with anticonvulsant properties (1,2). Sumatriptan Succinate is used for migraine relief (2).

Preparation methods · 1 item

PreparationMethod 1: Using 4-hydrazino-N-methylbenzylsulfonamide hydrochloride and 4,4-dimethoxy-N,N-dimethyl-butylamine as starting materials, polyphosphoric acid and sodium dihydrogen phosphate were used as catalysts. The post-treatment employed isopropyl ether and acetone as recrystallization solvents. Sumatriptan succinate was synthesized through a four-step reaction involving condensation, rearrangement, cyclization, and salt formation, with an overall yield of 12.7%. Method 2: 1. Sodium 4-chlorobutane-1,1-disulfonate was prepared by reacting 4-chlorobutanal with an aqueous solution of sodium metabisulfite, followed by filtration and drying. 2. 4-hydrazino-N-methylbenzylsulfonamide hydrochloride and sodium 4-chlorobutane-1,1-disulfonate were reacted under heating in the presence of an inorganic or organic acid catalyst. The reaction solution was adjusted to neutral with an alkaline solution, and the mixture was extracted with an organic solvent to obtain 3-(2-chloroethyl)-N-methyl-1H-indole-5-methanesulfonamide. 3,3-(2-chloroethyl)-N-methyl-1H-indole-5-methanesulfonamide was used as a phase transfer catalyst to react with dimethylamine. After the reaction was completed, the product was extracted, decolorized and purified to obtain a high-quality sumatriptan. The product was then dissolved in a solvent by heating, and succinic acid was added to form a salt. After crystallization, a white final product, sumatriptan succinate, was obtained.

Upstream & downstream products

Upstream raw materials

4-Hydrazino-N-Methyl Benzene Methane Sulphonamide Hydrochloride

Downstream products

Sumatriptan
Additional notes · 1 item

DefinitionChEBI: A succinate salt obtained by reaction of sumatriptan with one equivalent of succinic acid. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used for the acute treatm nt of migraine with or without aura in adults.